1. Home
  2. ELS vs CYTK Comparison

ELS vs CYTK Comparison

Compare ELS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ELS

Equity Lifestyle Properties Inc.

HOLD

Current Price

$65.42

Market Cap

12.8B

Sector

Real Estate

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$80.66

Market Cap

10.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELS
CYTK
Founded
1992
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.8B
10.7B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
ELS
CYTK
Price
$65.42
$80.66
Analyst Decision
Buy
Strong Buy
Analyst Count
10
19
Target Price
$70.25
$89.26
AVG Volume (30 Days)
1.5M
1.7M
Earning Date
04-21-2026
05-05-2026
Dividend Yield
3.49%
N/A
EPS Growth
2.55
N/A
EPS
0.56
N/A
Revenue
$1,531,382,000.00
$13,368,000.00
Revenue This Year
$3.97
$7.37
Revenue Next Year
$4.69
$310.19
P/E Ratio
$116.16
N/A
Revenue Growth
0.34
N/A
52 Week Low
$57.63
$32.89
52 Week High
$69.00
$88.31

Technical Indicators

Market Signals
Indicator
ELS
CYTK
Relative Strength Index (RSI) 55.03 52.43
Support Level $61.39 $59.07
Resistance Level $65.96 $88.31
Average True Range (ATR) 1.34 3.03
MACD 0.07 -0.59
Stochastic Oscillator 62.99 40.34

Price Performance

Historical Comparison
ELS
CYTK

About ELS Equity Lifestyle Properties Inc.

Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company has a portfolio of 453 properties across the US with a higher concentration in the Sun Belt; 38% of its properties are in Florida, 11% in Arizona, and 10% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: